Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.

Passiglia F, Pilotto S, Facchinetti F, Bertolaccini L, Del Re M, Ferrara R, Franchina T, Malapelle U, Menis J, Passaro A, Ramella S, Rossi G, Trisolini R, Novello S.

Crit Rev Oncol Hematol. 2019 Dec 28;146:102858. doi: 10.1016/j.critrevonc.2019.102858. [Epub ahead of print] Review.

PMID:
31918343
2.

Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis.

De Luca C, Sgariglia R, Nacchio M, Pisapia P, Migliatico I, Clery E, Gragnano G, Campione S, Vigliar E, Malapelle U, De Dominicis G, Bellevicine C, Troncone G.

Diagn Cytopathol. 2020 Jan 6. doi: 10.1002/dc.24378. [Epub ahead of print]

PMID:
31904908
3.

Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Pepe F, Pisapia P, Del Basso de Caro ML, Conticelli F, Malapelle U, Troncone G, Martinez JC.

Histol Histopathol. 2019 Dec 24:18195. doi: 10.14670/HH-18-195. [Epub ahead of print]

PMID:
31872418
4.

Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.

Bellevicine C, Migliatico I, Sgariglia R, Nacchio M, Vigliar E, Pisapia P, Iaccarino A, Bruzzese D, Fonderico F, Salvatore D, Biondi B, Masone S, Novizio V, Scavuzzo F, Serino D, De Palma M, Chiofalo MG, Botti G, Pezzullo L, Nuzzo V, Spiezia S, De Chiara G, Iorio S, Conzo G, Docimo G, Faggiano A, Bongiovanni M, Malapelle U, Colao A, Triassi M, Troncone G; Tiroide Network.

Cancer Cytopathol. 2019 Dec 10. doi: 10.1002/cncy.22217. [Epub ahead of print]

PMID:
31821746
5.

Lung Cancer in Italy.

Passiglia F, Calandri M, Guerrera F, Malapelle U, Mangone L, Ramella S, Trisolini R, Novello S.

J Thorac Oncol. 2019 Dec;14(12):2046-2052. doi: 10.1016/j.jtho.2019.05.019. No abstract available.

PMID:
31757374
6.

EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing.

Lettig L, Sahnane N, Pepe F, Cerutti R, Albeni C, Franzi F, Veronesi G, Ogliari F, Pastore A, Tuzi A, Pinotti G, Bovio A, Verusio C, Giordano M, Troncone G, Sessa F, Malapelle U, Furlan D.

Transl Lung Cancer Res. 2019 Oct;8(5):584-592. doi: 10.21037/tlcr.2019.09.18.

7.

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, Fusco N.

Int J Mol Sci. 2019 Nov 1;20(21). pii: E5452. doi: 10.3390/ijms20215452. Review.

8.

Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?

Malapelle U, Rossi A, Bria E.

J Thorac Dis. 2019 Sep;11(Suppl 15):S1837-S1840. doi: 10.21037/jtd.2019.08.99. No abstract available.

9.

Liquid biopsy tracking of lung tumor evolutions over time.

Russo A, De Miguel Perez D, Gunasekaran M, Scilla K, Lapidus R, Cooper B, Mehra R, Adamo V, Malapelle U, Rolfo C.

Expert Rev Mol Diagn. 2019 Dec;19(12):1099-1108. doi: 10.1080/14737159.2020.1680287. Epub 2019 Oct 16.

PMID:
31608732
10.

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.

Bianco A, Perrotta F, Barra G, Malapelle U, Rocco D, De Palma R.

Int J Mol Sci. 2019 Oct 5;20(19). pii: E4931. doi: 10.3390/ijms20194931. Review.

11.

USP11 role in colorectal cancer growing and metastatisation.

Malapelle U.

EBioMedicine. 2019 Oct;48:5-6. doi: 10.1016/j.ebiom.2019.09.022. Epub 2019 Sep 17. No abstract available.

12.

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.

Villatoro S, Mayo-de-Las-Casas C, Jordana-Ariza N, Viteri-Ramírez S, Garzón-Ibañez M, Moya-Horno I, García-Peláez B, González-Cao M, Malapelle U, Balada-Bel A, Martínez-Bueno A, Campos R, Reguart N, Majem M, Blanco R, Blasco A, Catalán MJ, González X, Troncone G, Karachaliou N, Rosell R, Molina-Vila MA.

Mol Oncol. 2019 Dec;13(12):2633-2645. doi: 10.1002/1878-0261.12574. Epub 2019 Oct 11.

13.

Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Malapelle U, Rolfo C; International Society of Liquid Biopsy (ISLB).

Cancer. 2020 Jan 1;126(1):22-25. doi: 10.1002/cncr.32482. Epub 2019 Sep 10. No abstract available.

PMID:
31503330
14.

Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas.

Covelli C, Parente P, Pepe F, Pisapia P, Fiordelisi F, Malapelle U.

Hepatobiliary Pancreat Dis Int. 2019 Oct;18(5):491-492. doi: 10.1016/j.hbpd.2019.08.003. Epub 2019 Aug 22. No abstract available.

PMID:
31477525
15.

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.

Banna GL, Olivier T, Rundo F, Malapelle U, Fraggetta F, Libra M, Addeo A.

Front Med (Lausanne). 2019 Jul 31;6:172. doi: 10.3389/fmed.2019.00172. eCollection 2019.

16.

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E.

Ther Adv Med Oncol. 2019 May 10;11:1758835919846421. doi: 10.1177/1758835919846421. eCollection 2019.

17.

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.

Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group.

Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.

18.

Bird's eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018.

Pisapia P, Bellevicine C, Malapelle U, De Luca C, Vigliar E, Troncone G.

Cancer Cytopathol. 2019 May 28. doi: 10.1002/cncy.22118. [Epub ahead of print] Review.

PMID:
31135103
19.

The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience.

Vigliar E, Malapelle U, Bono F, Fusco N, Cortinovis D, Valtorta E, Spyridon A, Bimbatti M, Zocchi M, Piva C, Gaudioso G, Iaccarino A, Morbini P, Pagni F.

Biomed Res Int. 2019 Apr 14;2019:6832909. doi: 10.1155/2019/6832909. eCollection 2019.

20.

Is the Idylla EGFR Mutation Assay feasible on archival stained cytological smears? A pilot study.

De Luca C, Conticelli F, Leone A, Gragnano G, Salatiello M, Galasso P, Pisapia P, Grillo LR, Iaccarino A, Vigliar E, Bellevicine C, Malapelle U, Troncone G.

J Clin Pathol. 2019 Sep;72(9):609-614. doi: 10.1136/jclinpath-2019-205863. Epub 2019 May 20.

PMID:
31110050
21.

Emerging angiogenesis inhibitors for non-small cell lung cancer.

Malapelle U, Rossi A.

Expert Opin Emerg Drugs. 2019 Jun;24(2):71-81. doi: 10.1080/14728214.2019.1619696. Epub 2019 May 22.

PMID:
31092048
22.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
23.

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.

Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M.

Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9.

PMID:
30967421
24.

Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment.

Vigliar E, Pepe F, Migliatico I, Nacchio M, Cesaro S, Della Pepa R, Bellevicine C, Malapelle U, Fassan M, Pane F, Picardi M, Troncone G.

Diagn Cytopathol. 2019 Aug;47(8):749-757. doi: 10.1002/dc.24184. Epub 2019 Apr 5.

PMID:
30953406
25.

Role of Cytomorphology in the Era of Liquid Biopsy.

Clery E, Pisapia P, Vigliar E, Malapelle U, Bellevicine C, Troncone G, Schmitt FC.

Acta Cytol. 2019;63(6):497-505. doi: 10.1159/000499338. Epub 2019 Apr 3. Review.

PMID:
30943469
26.

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?

Friedlaender A, Banna G, Malapelle U, Pisapia P, Addeo A.

Front Oncol. 2019 Mar 19;9:166. doi: 10.3389/fonc.2019.00166. eCollection 2019. Review.

27.

PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.

Vigliar E, Malapelle U, Iaccarino A, Acanfora G, Pisapia P, Clery E, De Luca C, Bellevicine C, Troncone G.

J Clin Pathol. 2019 Jun;72(6):412-417. doi: 10.1136/jclinpath-2019-205732. Epub 2019 Mar 7.

PMID:
30846480
28.

BRAF Mutations in Lung Cancer.

Pisapia P, Pepe F, Malapelle U, Troncone G.

Acta Cytol. 2019;63(3):247-250. doi: 10.1159/000496478. Epub 2019 Mar 6. No abstract available.

PMID:
30840950
29.

Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture.

Pallante P, Pisapia P, Bellevicine C, Malapelle U, Troncone G.

Acta Cytol. 2019;63(3):171-181. doi: 10.1159/000496213. Epub 2019 Feb 13. Review.

30.

Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.

Malapelle U, Raez LE, Serrano MJ, Rolfo C; International Society of Liquid Biopsies (ISLB).

J Thorac Dis. 2018 Dec;10(12):6388-6391. doi: 10.21037/jtd.2018.11.22. No abstract available.

31.

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.

Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G.

Cancers (Basel). 2019 Jan 27;11(2). pii: E147. doi: 10.3390/cancers11020147.

32.

Liquid Biopsy and Lung Cancer.

Pisapia P, Malapelle U, Troncone G.

Acta Cytol. 2019;63(6):489-496. doi: 10.1159/000492710. Epub 2018 Dec 19. Review.

PMID:
30566947
33.

Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.

Malapelle U, Iaccarino A, Rossi A.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S221-S224. doi: 10.21037/tlcr.2018.08.09. No abstract available.

34.

Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study.

Scimia M, Du J, Pepe F, Bianco MA, Russo Spena S, Patell-Socha F, Sun Q, Powell MJ, Malapelle U, Troncone G.

J Clin Pathol. 2018 Dec;71(12):1123-1126. doi: 10.1136/jclinpath-2018-205412. Epub 2018 Oct 12.

PMID:
30315134
35.

Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients.

Capo A, Sepe R, Pellino G, Milone M, Malapelle U, Pellecchia S, Pepe F, Cacciola NA, Manigrasso M, Bruzzaniti S, Sciaudone G, De Palma GD, Galgani M, Selvaggi F, Troncone G, Fusco A, D'Auria S, Pallante P.

Nanomedicine. 2019 Jan;15(1):231-242. doi: 10.1016/j.nano.2018.09.011. Epub 2018 Oct 9.

PMID:
30308301
36.

Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.

Pepe F, De Luca C, Smeraglio R, Pisapia P, Sgariglia R, Nacchio M, Russo M, Serra N, Rocco D, Battiloro C, Ambrosio F, Gragnano G, Vigliar E, Bellevicine C, Troncone G, Malapelle U.

J Clin Pathol. 2019 Jan;72(1):38-45. doi: 10.1136/jclinpath-2018-205386. Epub 2018 Oct 2.

PMID:
30279174
37.

Osimertinib.

Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G.

Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. Review.

PMID:
30069773
38.

Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives.

Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F.

Gastroenterol Res Pract. 2018 Jun 13;2018:2397863. doi: 10.1155/2018/2397863. eCollection 2018. Review.

39.

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.

Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E.

Oncotarget. 2018 May 29;9(41):26279-26290. doi: 10.18632/oncotarget.25180. eCollection 2018 May 29.

40.

Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.

De Luca C, Rappa AG, Gragnano G, Malapelle U, Troncone G, Barberis M.

J Clin Pathol. 2018 Aug;71(8):745-750. doi: 10.1136/jclinpath-2018-205197. Epub 2018 May 24.

PMID:
29798838
41.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

42.

Targeting immune checkpoints in non small cell lung cancer.

Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G.

Curr Opin Pharmacol. 2018 Jun;40:46-50. doi: 10.1016/j.coph.2018.02.006. Epub 2018 Mar 9. Review.

PMID:
29525401
43.

Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.

Bellevicine C, Sgariglia R, Migliatico I, Vigliar E, D'Anna M, Nacchio MA, Serra N, Malapelle U, Bongiovanni M, Troncone G.

Cancer Cytopathol. 2018 May;126(5):317-325. doi: 10.1002/cncy.21984. Epub 2018 Feb 22.

44.

Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting.

Pisapia P, Pepe F, Smeraglio R, Russo M, Rocco D, Sgariglia R, Nacchio M, De Luca C, Vigliar E, Bellevicine C, Troncone G, Malapelle U.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1383-S1390. doi: 10.21037/jtd.2017.06.97.

45.

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.

Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, Malapelle U, Karachaliou N, Troncone G, Rosell R, Molina-Vila MA.

Expert Rev Mol Diagn. 2018 Jan;18(1):35-45. doi: 10.1080/14737159.2018.1407243. Epub 2017 Nov 26. Review.

PMID:
29172773
46.

ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.

Pisapia P, Lozano MD, Vigliar E, Bellevicine C, Pepe F, Malapelle U, Troncone G.

Cancer Cytopathol. 2017 Nov;125(11):817-830. doi: 10.1002/cncy.21899. Epub 2017 Jul 25. Review.

47.

How to prepare cytological samples for molecular testing.

Bellevicine C, Malapelle U, Vigliar E, Pisapia P, Vita G, Troncone G.

J Clin Pathol. 2017 Oct;70(10):819-826. doi: 10.1136/jclinpath-2017-204561. Epub 2017 Jul 24. Review.

PMID:
28739858
48.

Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?

De Stefano A, Rosanova M, Malapelle U, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C.

Int J Biol Markers. 2017 Oct 31;32(4):e474-e477. doi: 10.5301/ijbm.5000273.

PMID:
28665451
49.

Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs.

Malapelle U, Pallante P.

Front Med (Lausanne). 2017 May 22;4:63. doi: 10.3389/fmed.2017.00063. eCollection 2017. No abstract available.

50.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

Supplemental Content

Loading ...
Support Center